Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. Its biotechnology products include BeneFIX, ReFacto and Xyntha. The Company's contract manufacturing business, Pfizer CentreOne, consists of its contract manufacturing and active pharmaceutical ingredient sales operation, including manufacturing and supply agreements with Zoetis Inc., and Hospira's One-2-One sterile injectables contract manufacturing operation. Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases. The Company's subsidiaries include Hospira, Inc. and Medivation, Inc.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: Pharmaceuticals
- Exchange: NYSE
- Symbol: PFE
- CUSIP: 71708110
- Previous Close: $34.26
- 50 Day Moving Average: $32.47
- 200 Day Moving Average: $32.92
- 52-Week Range: $28.74 - $37.39
- Trailing P/E Ratio: 29.21
- Foreward P/E Ratio: 12.28
- P/E Growth: 2.13
- Market Cap: $207.90B
- Outstanding Shares: 6,068,354,000
- Beta: 0.94
- Net Margins: 13.50%
- Return on Equity: 23.18%
- Return on Assets: 8.60%
Companies Related to Pfizer:
- Debt-to-Equity Ratio: 0.48%
- Current Ratio: 1.11%
- Quick Ratio: 0.89%
What is Pfizer's stock symbol?
Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."
How often does Pfizer pay dividends? What is the dividend yield for Pfizer?
Pfizer declared a quarterly dividend on Monday, December 12th. Investors of record on Friday, February 3rd will be given a dividend of $0.32 per share on Wednesday, March 1st. This represents a $1.28 dividend on an annualized basis and a yield of 3.74%. The ex-dividend date is Wednesday, February 1st. This is a boost from Pfizer's previous quarterly dividend of $0.30.
Where is Pfizer's stock going? Where will Pfizer's stock price be in 2017?
21 analysts have issued 12-month price objectives for Pfizer's shares. Their forecasts range from $33.00 to $53.00. On average, they expect Pfizer's stock price to reach $37.59 in the next year.
When will Pfizer announce their earnings?
Pfizer is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.
What are analysts saying about Pfizer stock?
Here are some recent quotes from research analysts about Pfizer stock:
According to Zacks Investment Research, "Pfizer has been working on strengthening its product portfolio as well as pipeline through acquisitions and licensing deals. While the Hospira acquisition significantly expanded Pfizer's sterile injectable and biosimilar capabilities, the Medivation deal strengthened its cancer franchise by adding Xtandi to its portfolio. Pfizer’s new products like Ibrance should do well and drive revenues in 2017 while cost-savings and share buybacks should boost earnings. Pfizer’s shares surpassed that of large-cap pharma industry in the past one year. The company has a positive record of earnings surprises in recent quarters. Investor focus will remain on the stock as Pfizer has several key pipeline milestones in 2017. However, headwinds remain in the form of genericization, pricing pressure and rising competition, which will continue to hamper top-line growth. Estimates have declined slightly ahead of its Q4 earnings release." (1/25/2017)
Jefferies Group LLC analysts commented, "We wanted to highlight a key data catalyst in which a positive outcome can drive shares higher: PIIa data for XEN801 for mod-to-severe acne in the latter part of Q1 (JEF est: ~Mar). We continue to like the risk/reward going into the data, especially on the heels of Dermira’s positive PIIb data for DRM01, which operates on the same pathway but more upstream. Reiterating Buy and $13 PT. Highlighting Key PIIa Data Catalyst in Latter Part of Q1: We wanted to take the opportunity to highlight a key data catalyst in which a positive outcome can drive shares higher: topline PIIa data catalyst for XEN801 for moderate-to-severe acne in the latter part of Q1 (JEF estimate: ~Mar). We previously conducted a review on XEN801 in April ’16, which can be found here, and now that the data catalyst is drawing near, we wanted to take the chance to highlight it again. To recap, the PIIa trial is a randomized, double- blind, multicentre, vehicle-controlled trial evaluating the efficacy and safety of patients with moderate-to-severe acne. The trial will compare XEN801 topical gel (1%) and matching placebo gel for 12 weeks with a 4-week follow-up. XENE has randomized 165 patients (v. 150 that was planned at conception), and has 85% power (v. 80% previously) to detect a ~16% difference." (1/19/2017)
Who owns Pfizer stock?
Pfizer's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (5.29%), Barrow Hanley Mewhinney & Strauss LLC (0.75%), Franklin Resources Inc. (0.72%), Dimensional Fund Advisors LP (0.66%), FMR LLC (0.36%) and FIL Ltd (0.31%). Company insiders that own Pfizer stock include Albert Bourla, Anthony J Maddaluna, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc and Sally Susman.
Who sold Pfizer stock? Who is selling Pfizer stock?
Pfizer's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nokota Management LP, Barrow Hanley Mewhinney & Strauss LLC, Thornburg Investment Management Inc., Nicholas Co. Inc. WI, Janus Capital Management LLC, Artemis Investment Management LLP and FIL Ltd. Company insiders that have sold Pfizer stock in the last year include Albert Bourla, Anthony J Maddaluna, Douglas M Lankler, Frank A Damelio, Ian C Read, John D Young, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten and Sally Susman.
Who bought Pfizer stock? Who is buying Pfizer stock?
Pfizer's stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., State Street Corp, Asset Management One Co. Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Appaloosa LP, FMR LLC, I.G. Investment Management LTD. and Marshall Wace LLP.
How do I buy Pfizer stock?
Shares of Pfizer can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Pfizer stock cost?
One share of Pfizer stock can currently be purchased for approximately $34.26.